In vitro sensitivity of macropodid herpesvirus 2 to selected anti-herpetic compounds.
We tested the in vitro sensitivity of Macropodid Herpesvirus 2 to eight commonly used anti-herpetic compounds using plaque reduction tests, March and April, 1995. The virus was most susceptible to inhibition by (E)-5-(2'-bromovinyl)-2'-deoxyuridine and adenine 9-beta-D-arabino-furanoside. Both compounds have been used for anti-herpetic therapy in humans and may prove useful in the treatment of macropodoids in captivity.
Smith
G
G
Queensland Agricultural Biotechnology Centre, Queensland Department of Primary Industries, University of Queensland, St. Lucia, Australia.
D000212:Acyclovir / Q000494:pharmacology; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D001087:Arabinonucleosides / Q000494:pharmacology; D001972:Bromodeoxycytidine / Q000031:analogs & derivatives; D001973:Bromodeoxyuridine / Q000031:analogs & derivatives / Q000494:pharmacology; D002460:Cell Line; D003561:Cytarabine / Q000494:pharmacology; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000494:pharmacology; D006564:Herpesviridae / Q000187:drug effects*; D006566:Herpesviridae Infections / Q000662:veterinary* / Q000821:virology; D007065:Idoxuridine / Q000494:pharmacology; D007614:Macropodidae / Q000821:virology*; D008826:Microbial Sensitivity Tests / Q000662:veterinary; D009500:Neutralization Tests / Q000662:veterinary; D013936:Thymidine / Q000031:analogs & derivatives / Q000494:pharmacology; D014271:Trifluridine / Q000494:pharmacology; D014740:Vidarabine / Q000494:pharmacology
D000998:Antiviral Agents; D001087:Arabinonucleosides; D003561:Cytarabine; D003841:Deoxycytidine; D001972:Bromodeoxycytidine; C020235:brivudine; C011288:ibacitabine; D014740:Vidarabine; D001973:Bromodeoxyuridine; D007065:Idoxuridine; C010032:thymine arabinoside; D014271:Trifluridine; D013936:Thymidine; D000212:Acyclovir